Kenneth Bradley
Ken Bradley serves as the Global Head of Discovery for Infectious Disease, where he oversees early research efforts in the AMR and viral field. He came to Roche in 2015 to lead Roche’s re-entry into antibiotics R&D aimed at addressing multidrug resistant bacteria. Prior to this, Ken was a Professor of Microbiology, Immunology and Molecular Genetics at the University of California, Los Angeles and served as the Director of the Molecular Screening Shared Resource, a high throughput screening center at the California NanoSystems Institute. Roche currently has two novel class antibiotics for gram-negative bacterial infections in clinical development – one focused on the treatment of carbapenem-resistant Acinetobacter baumannii, and one focused on the treatment of carbapenem-resistant gram-negative infections.